Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: seminole who wrote (1280)	3/15/2002 5:30:27 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 1475

No. I honestly believe that they didn't understand the implications of tickling an epitope of CD2, and had interest in other parts of the pipeline that subsequently failed. They had used it as a hammer for GvH, and I don't believe that rationale could penetrate a given ego at MEDI. I believe that they're rushing like crazy to make up for lost time. Hope so. But..... the bottom line is that they sort of "made up" the conclusions in that phase II PR. The results from the i.v. trial were sort of massaged to fit the assumption of what should be, given the subcutaneous results and (IMO) the entrenched ego. With one more brain, MEDI could have been an enormous success story. PROVE ME WRONG, JIMMIE!